Exchange: NYSE·Updated 07:52 PM EDT
News
all
press releases
Fresenius Medical Care (FMS) Q2 2026 Earnings Call Transcript
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets
More News
FMS Q2 Earnings Rise on Care Delivery, Revenues Miss, Margins Expand
FMS posts 28% EPS growth as Care Delivery profitability and margin gains offset a quarterly revenue miss and weaker US treatment volumes.
Zacks
Fresenius Medical Care Q2 2026 Earnings Call Transcript
Fresenius Medical Care (NYSE:FMS) held its second-quarter earnings conference call on Tuesday. Below is the complete transcript from the call. Benzinga APIs provide real-time access to earnings call transcripts andread more...
Benzinga
Reasons to Retain Fresenius Medical Stock in Your Portfolio for Now
FMS??? margin gains, HighVolumeHDF rollout and AI-driven care are boosting momentum, but reimbursement and volume risks remain.
Zacks
DaVita Stock Benefits From Strengthening Kidney Care Delivery
DVA is advancing kidney care through IKC expansion, CMS CKCC progress and AI-driven dialysis scheduling improvements.
Zacks
DVA vs. FMS: Which Dialysis Leader Is Better Positioned Now?
DaVita and Fresenius Medical Care are taking different paths in kidney care, but which stock offers stronger upside now? Let's dive in.
Zacks
FMS and Home Dialysis: How 5008X Could Reset Demand
FMS scales 5008X high-volume HDF and expands home dialysis, aiming for benefits later in 2026 and a bigger payoff in 2027+.
Zacks
FMS Launches kinexus Digital Platform for Home Dialysis Care
Fresenius Medical Care launches kinexus, a home dialysis platform integrating remote monitoring, prescription management and supply ordering for PD and HHD.
Zacks
DaVita Expands Comprehensive Kidney Care Through Dialysis Services
DVA expands kidney-care reach with integrated CKD/ESKD coordination and 2026 AI scheduling tech to boost dialysis efficiency.
Zacks
DaVita Gains 21.4% in Three Months: How Should You Play the Stock?
DVA raises guidance on stronger dialysis volumes and reimbursement gains, but rising patient-care and technology costs could squeeze margins.
Zacks

Advertisement|Remove ads.